ClinConnect ClinConnect Logo
Search / Trial NCT03638466

Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD

Launched by SUPERNUS PHARMACEUTICALS, INC. · Aug 16, 2018

Trial Information

Current as of May 25, 2025

Terminated

Keywords

ClinConnect Summary

Approximately 30 subjects aged 8-12 diagnosed with ADHD and associated feature of IA were recruited in this study. The PSAP is a behavioral aggression test used to evaluate behavioral response related to impulsive aggression. The task was combined with functional MRI to evaluate the change in brain activity measured as BOLD signal (blood oxygenation level-dependent) from baseline to the end of the treatment with SPN-810.

The level of neurotransmitters Glutamate and GABA were also measured using magnetic resonance spectroscopy (MRS).

Additionally, the improvement and severity in impulsive ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Otherwise healthy male or female subjects, aged 8-12 years, inclusive, at the time of screening with primary diagnosis of ADHD and currently receiving monotherapy treatment with an optimized US Food and Drug Administration (FDA)-approved ADHD medication.
  • Impulsive aggression (IA) confirmed at screening using the R-MOAS and the Vitiello Aggression Scale.
  • Exclusion Criteria:
  • Current or lifetime diagnosis of epilepsy, major depressive disorder, bipolar disorder, schizophrenia or related disorder, personality disorder, Tourette's disorder, fetal alcohol syndrome, or psychosis not otherwise specified.
  • Currently meeting DSM criteria for autism spectrum disorder, pervasive developmental disorder, obsessive-compulsive disorder, post-traumatic stress disorder.
  • Known or suspected IQ \<70, pregnancy, substance or alcohol abuse.
  • Known history of implanted brain stimulator, vagal nerve stimulator, ventriculoperitoneal shunt, cardiac pacemaker, orthodontic braces, or implanted medication port. Visual and hearing (≥25 dB) impairment.
  • Pre-existing medical or psychological conditions that preclude being in the MRI scanner (e.g., claustrophobia, morbid obesity, or marked anxiety about the procedure).

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialized pharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders, particularly epilepsy and ADHD. With a commitment to addressing unmet medical needs, Supernus leverages its expertise in formulation development and drug delivery to bring novel treatment options to patients. The company’s robust pipeline reflects its dedication to enhancing patient outcomes through research-driven approaches and strategic partnerships, positioning Supernus as a leader in the pharmaceutical landscape.

Locations

Maitland, Florida, United States

Tampa, Florida, United States

Lakeland, Florida, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials